Carregant...

Cost-effectiveness Analysis of Nivolumab for Treatment of Platinum-Resistant Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

BACKGROUND: The CheckMate 141 trial found that nivolumab improved survival for patients with recurrent or metastatic head and neck cancer (HNC). Despite the improved survival, nivolumab is much more expensive than standard therapies. This study assesses the cost-effectiveness of nivolumab for the tr...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Natl Cancer Inst
Autors principals: Tringale, Kathryn R, Carroll, Kate T, Zakeri, Kaveh, Sacco, Assuntina G, Barnachea, Linda, Murphy, James D
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2017
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5946900/
https://ncbi.nlm.nih.gov/pubmed/29126314
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jnci/djx226
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!